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Human cytomegalovirus (CMV) is a common herpesvirus which is estimated to infect 83% of 23 
the global population. Whilst many infections are asymptomatic, it is an important cause of 24 
morbidity and mortality, particularly for immunocompromised people and for infants who 25 
are congenitally infected. A vaccine against CMV has been stated as a public health priority, 26 
but there are gaps in our understanding of CMV epidemiology. To guide potential future 27 
vaccination strategies, our aim was to examine risk factors for CMV seropositivity in young 28 
people in England. 29 
Methods 30 
The Health Survey for England (HSE) is an annual, cross-sectional representative survey of 31 
households in England during which data are collected through questionnaires, and blood 32 
samples are taken. We randomly selected individuals who participated in the HSE 2002, 33 
aiming for 25 participants of each sex in each single year age group from 11-24 years. Stored 34 
samples were tested for CMV antibodies. We undertook descriptive and regression analyses 35 
of CMV seroprevalence and risk factors for infection. 36 
Results 37 
Demographic data and serostatus were available for 732 individuals, of whom 175 (23.7%) 38 
were CMV-seropositive. CMV seroprevalence was associated with age, with 18.3% 39 
seropositive at 11-14 years compared to 28.3% at 22-24 years. CMV serostatus was also 40 
higher in people of non-white ethnicity (adjusted odds ratio [aOR] 6.22, 95% confidence 41 
interval [CI] 3.47-11.14), and in adults who were seropositive for EBV (aOR 2.08 [1.06-4.09]). 42 
There was no evidence that smoking status, occupation, body mass index and region of 43 
England were associated with CMV serostatus. 44 
Conclusions 45 
CMV seroprevalence is strongly associated with ethnicity, and modestly increases with age 46 
in 11-24-year-olds. A greater understanding of the transmission dynamics of CMV, and the 47 
impact of this on CMV-associated morbidity and mortality, is necessary to inform effective 48 
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The human cytomegalovirus (CMV) is a common human herpesvirus causing lifelong 54 
infections, and is estimated to infect 83% of the global population.1 CMV can be transmitted 55 
from symptomatic individuals, via saliva or other body fluids and blood products.2 Infection 56 
with CMV is typically subclinical in healthy individuals,3 however it is linked to multiple 57 
causes of morbidity and mortality. CMV accounts for around 5-8% of infectious 58 
mononucleosis cases,4,5 and causes disease in immunocompromised people such as 59 
transplant and cancer patients.3 Congenitally infected newborns can suffer from 60 
cytomegalic inclusion syndrome which can cause long-term neurological damage and, in 61 
some cases, life-threatening organ dysfunction.5 62 
CMV infection has been associated with shortened life expectancy, particularly in critically ill 63 
populations and immunocompromised people (such as those who have undergone organ 64 
transplants).6 In immunocompetent people in the UK, Gkrania-Klotsas et al. also found that 65 
CMV seropositivity was associated with lower life expectancy.6  This confirmed the 66 
association reported in a population-based cohort study from the US,7 as well as 67 
populations in older patients8 and those with cardiovascular disease.9 The association found 68 
in Gkrania-Klotsas et al. was specifically with deaths from causes other than cardiovascular 69 
disease and cancer, although high levels of CMV IgG antibodies were also associated with 70 
cardiovascular mortality.6 Other studies in the United States, Finland and United Kingdom 71 
found that, in immunocompetent individuals, CMV infection and higher levels of CMV IgG 72 
antibodies were linked to higher rates of both cardiovascular9 and all-cause mortality,7 as 73 
well as to cancer incidence10 and ischemic heart disease.11 However, CMV is negatively 74 
associated with multiple sclerosis onset.12 75 
In terms of biological pathways, it has been hypothesised that frequent silent reactivations 76 
of CMV infection lead to chronic inflammation, which may be a causal factor in the 77 
increased risk of mortality.6 Additionally, CMV seropositivity has been linked to telomere 78 
shortening of T cells, suggesting that CMV may be implicated in immunosenescence, 79 
thereby shortening life expectancy.2,13 There is also evidence for an immunological 80 
phenomenon called ‘memory inflation’, where a high proportion of CD8+ T cells in older 81 
CMV-positive individuals react to an epitope from a CMV protein.14 This may limit the ability 82 
of the immune system to respond to other infections and could be associated with CMV’s 83 
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ability to infect the vascular endothelium. CMV infection also drives large expansions of 84 
cytotoxic virus-specific CD4+ T cells in older individuals, which could ‘take up room’ in the 85 
immune system and potentially limit responses to other pathogens.15 86 
Given the implications of CMV infection, anti-CMV vaccines have been designated high 87 
priority by national health agencies, but to date no effective vaccines appear to be 88 
imminent.16,17 Mathematical modelling of the impact of different vaccination strategies can 89 
be used to guide vaccine development efforts and will be necessary to inform the optimal 90 
strategies for deployment of such a vaccine if or when it becomes available. A thorough 91 
understanding of CMV epidemiology is necessary for the development of such models. 92 
CMV seroprevalence increases with age, and infection occurs at younger ages in 93 
economically developing countries,2,6 possibly due to higher rates of breastfeeding than in 94 
the UK (CMV is known to be transmitted through breast milk). A large population-based UK 95 
cohort study found that CMV infection was more common in women than in men.6 Lower 96 
income and education levels, and ethnicities other than white, have been associated with 97 
earlier age at CMV infection.18 CMV infection is also correlated with EBV infection.19,20 98 
Socioeconomic status is strongly correlated with CMV infection; the reasons for this could 99 
include larger family size,21 or have been hypothesised to be a result of stress induced by 100 
low socioeconomic status contributing to the down-regulation of the immune system and 101 
increased susceptibility to infection.18 102 
To date in the UK, studies of CMV seroprevalence have focused on older adults,6 pregnant 103 
women,22 and young children.23,24 However transmission can occur at all ages, and the 104 
association of CMV with infectious mononucleosis suggests that infection during 105 
adolescence could also be an important cause of morbidity. Therefore, our aim was to 106 
investigate the sociodemographic and lifestyle factors, particularly age, associated with CMV 107 
serostatus in children and young adults in England, in order to gain a better understanding 108 
of the epidemiology of CMV in this age group. 109 
Methods 110 
Study population 111 
The Health Survey for England (HSE) is a cross-sectional annual representative survey of 112 
English households. The methods have been described previously.25 As part of a larger study 113 
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investigating Epstein-Barr virus infection and transmission,20,26 we used data from randomly 114 
selected participants in the 2002 HSE, aiming for 25 male and 25 female participants in each 115 
single-year age group from 11-24 years. 116 
Outcome: Seropositivity for Cytomegalovirus infection 117 
We used stored blood serum samples collected by the HSE. Commercial ELISA kits from 118 
EUROIMMUN, Germany (EI2791-9601-G, EI2570-9601G) were used to detect CMV-specific 119 
IgG and EBV virus capsid antigen (VCA)-specific IgG from the serum samples. Assays were 120 
conducted according to the manufacturer’s instructions, and we calculated serum antibody 121 
concentrations using a standard curve. Results were presented in relative units (RU/mL) 122 
using the following thresholds; samples of <16RU/mL were classed as negative, ≤16 to 123 
<22RU/mL were borderline, and ≥22RU/mL were positive. For the analyses presented here, 124 
borderline results (CMV n=1, EBV n=5) were considered seropositive.20 125 
Statistical Analysis 126 
We used Stata version 15.0 for data analysis. Stata’s svy commands were used to weight our 127 
sample to be representative of the age and sex of the 2002 English population, using data 128 
from the Office for National Statistics.27 All stated percentages are weighted. We conducted 129 
descriptive analyses of the study population. We used ArcMap 10.3.1 to map CMV 130 
seroprevalence by English Government Office Region.28 131 
We used logistic regression models to investigate factors associated with being seropositive 132 
for CMV. We used a causal inference framework to identify a priori factors that needed to 133 
be included in multivariable models, drawing on the available data from the HSE. This 134 
resulted in two multivariable regression models. We built a ‘whole-population’ model, 135 
which included our entire study population, to examine the following factors: age, sex, 136 
ethnicity (categorised as ‘white’ or ‘other’ due to small numbers of non-white participants), 137 
body mass index (BMI; categorised as ‘underweight’ [BMI <20], ‘healthy weight’ [20-25], 138 
‘overweight’ [25-30] or ‘obese’ [>30]), region of England and EBV serostatus. Additionally, 139 
we built a second ‘adults-only’ model, which only included participants aged ≥16 years, and 140 
additionally included data from questions which were only asked to adults; smoking status 141 
(never smoked, current smoker, smoked in past) and occupational category (higher 142 
managerial and professional, intermediate occupations, routine and manual occupations, 143 
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never worked or long-term unemployed, and other). Individuals missing data on one or 144 
more variables were excluded from the regression modelling. 145 
Ethical approval 146 
This study was approved by the University College London Research Ethics Committee 147 
(5683/002). The HSE obtained informed written consent from participants at the time of 148 
recruitment for blood samples to be collected and stored for future analyses.[15] A 149 
parent/guardian of participants also provided written consent for the interviewing of 150 
participants who were younger than 16 years, and for the taking of blood samples from 151 
participants who were younger than 18 years. 152 
Results 153 
Our study sample included 732 individuals aged 11-24 years, of whom 175 (23.7%) were 154 
CMV-seropositive. Seroprevalence by participant characteristics are shown in Table 1. There 155 
was a slight increase in CMV seropositivity associated with age, from 18.3% at 11-14 years 156 
to 28.3% at 22-24 years. CMV seroprevalence was much lower in white people (19.2%) than 157 
people of other ethnicities (61.6%). Considerable variation in CMV seroprevalence was 158 
observed by region of England (Figure 1, Table 1), being highest in London (47.9%) and 159 
otherwise varying between 16.7% in the south-east and 28.7% in the east of England. CMV 160 
serostatus was also higher in women (26.9%) than in men (20.4%) and people who were 161 
EBV-seropositive (25.7%) than EBV-seronegative (17.9%). 162 
Univariable and multivariable regression models were built examining the factors associated 163 
with CMV positivity. Factors associated with CMV seropositivity were largely consistent 164 
between the univariable and multivariable models (Table 2), although confidence intervals 165 
tended to be wider in the multivariable models. Ethnicities other than white were strongly 166 
associated with CMV seropositivity in both univariable and multivariable models (adjusted 167 
odds ratio [aOR] 6.22, 95% confidence interval [CI] 3.47-11.14). EBV serostatus was 168 
associated with CMV serostatus in the univariable model (odds ratio [OR] 1.59 [1.06-2.39] 169 
and in the adults-only multivariable model (aOR 2.08 [1.06-4.09]), but not in the 170 
multivariable model which included children (aOR 1.21 [0.76-1.92]). Female sex was 171 
associated with higher CMV positivity in the univariable model (OR 1.44, 1.02-2.02); the 172 
multivariable models had similar point estimates, but the confidence intervals included 173 
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unity. Region of England was not associated with CMV serostatus in multivariable models. 174 
Neither smoking status nor occupation were associated with CMV serostatus in adults. 175 
Our study sample included 732 individuals aged 11-24 years, of whom 175 (23.7%) were 176 
CMV-seropositive. The characteristics of seropositive individuals are shown in Table 1. 177 
Univariable and multivariable regression models were built examining the factors associated 178 
with CMV positivity. Factors associated with CMV seropositivity were largely consistent 179 
between the univariable and multivariable models (Table 2), although confidence intervals 180 
tended to be wider in the multivariable models. 181 
There was an increase in CMV seropositivity associated with age, from 18.3% at 11-14 years 182 
to 28.3% at 22-24 years, but the confidence intervals between strata overlapped in logistic 183 
regression models. CMV seroprevalence was much higher in people of non-white ethnicities 184 
than in white people (61.6% vs 19.2%; aOR 6.22, 95% CI 3.47-11.14). CMV serostatus was 185 
also higher in women (26.9%) than in men (20.4%); the CI for this association excluded unity 186 
in a univariable model (odds ratio [OR] 1.44, 95% confidence interval [CI] 1.02-2.02); the 187 
multivariable models had similar point estimates, but the confidence intervals included 188 
unity. Neither smoking status nor occupation were associated with CMV serostatus in 189 
adults. 190 
CMV seropositivity was higher in people who were EBV-seropositive (25.7%) than EBV-191 
seronegative (17.9%). EBV serostatus was associated with CMV serostatus in the univariable 192 
model (OR 1.59 [1.06-2.39] and in the adults-only model (aOR 2.08 [1.06-4.09]), but not in 193 
the multivariable model which included children (aOR 1.21 [0.76-1.92]). 194 
Considerable variation in CMV seroprevalence was observed by region of England (Figure 1, 195 
Table 1), CMV seroprevalence was highest in London (47.9%) and otherwise varied between 196 
16.7% in the south-east to 28.7% in the east of England. However, region of England was not 197 
associated with CMV serostatus in multivariable models.  198 
Discussion 199 
In this study of young people in England, we found that just under a quarter of people aged 200 
11-24 years were infected with CMV, and that seroprevalence increased over this age range. 201 
CMV infection was also strongly correlated with non-white ethnicity and more weakly 202 
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associated with EBV infection. There was no association observed between CMV and region 203 
of England, smoking status, BMI, or occupation. 204 
CMV and EBV serostatus were positively associated in univariable analyses, and when the 205 
multivariable analysis was restricted to adults, but not in the multivariable model which also 206 
included children aged 11-15 years. As discussed in our previous paper,20 both CMV and EBV 207 
are associated with increasing age, however EBV increases more rapidly during adolescence 208 
than CMV. Thus, in a whole-cohort model adjusting for age, this association may not be 209 
visible. As the associations between age and both CMV and EBV20 are less strong in adults, it 210 
is possible that there was enough of a residual effect that the association between CMV and 211 
EBV could be detected in the adults-only model. 212 
 Given the cross-sectional nature of our study, the relative temporality of the two infections 213 
could not be assessed.  Although established, the relationship between CMV and EBV is not 214 
well understood. It is known that EBV seroprevalence is higher than CMV seroprevalence in 215 
all age groups and that both increase with age,20 but it is not known whether this 216 
relationship is causal or whether the association results from shared genetic, immunological 217 
and/or sociodemographic risk factors. Longitudinal studies with serial testing and a larger 218 
sample size would be necessary to explore this association in more detail. 219 
We observed a strong association between ethnicity and CMV seroprevalence; the odds of 220 
being CMV positive were approximately seven time higher for people of ethnicities other 221 
than white than the odds for white people. This may be the result of different social mixing 222 
patterns, larger households, different eating or hygiene habits, lower breastfeeding rates in 223 
white people (resulting in less vertical transmission of CMV through breastmilk), possibly 224 
different countries of birth (of participants or their parents) or residual confounding of 225 
socioeconomic status. This strong association with ethnicity is also likely to be a confounder 226 
in the association between CMV and region, particularly London, that was only observed in 227 
univariable models, as there is a higher proportion of ethnic minorities living in London than 228 
elsewhere in England.29 We were unable to analyse associations with ethnicity in more 229 
detail due to small numbers of participants; the “non-white” group comprised 57% 230 
Asian/Asian British (n=44), 19% black/black British (n=15), 14% mixed ethnicity (n=11) and 231 
9% other ethnicity (n=7). Further study of the association of ethnicity with CMV 232 
seroprevalence is needed in diverse cohorts.  233 
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Our study benefits from a sample drawn from a highly rigorous, annual, representative 234 
survey of people in England, which we weighted to be representative of the English 235 
population, and the use of a quality-managed commercial assay to measure the antibody 236 
response. The limitations of our work include the use of a cross-sectional study design, 237 
preventing determination of the temporality of certain associations, and the age of the data; 238 
2002 was the most recent year for which the HSE collected consent to analyse blood 239 
samples for blood-borne viruses. More recent data from the UK biobank found that 58% of 240 
those aged 40-69 years were seropositive for CMV at enrolment (2006-2010),30 and as CMV 241 
seroprevalence increases with age throughout life, the prevalence observed in young people 242 
in our study is consistent with what could be expected. An older study examined CMV 243 
seroprevalence in 1991 and 2002 and found that prevalence in young people did not differ 244 
between these two timepoints,31 and so there is no particular reason to believe CMV 245 
seroprevalence has changed substantially since then. We also consider it unlikely that the 246 
associations between CMV and the risk factors we studied would have changed substantially 247 
since 2002, and therefore the associations we observed are likely to be consistent today 248 
even if there had been a slight change in CMV seroprevalence. 249 
The relatively low seroprevalence of CMV meant this study may have lacked power to 250 
detect associations, particularly in the multivariable models. We were also limited in the 251 
variables that were available, we were unfortunately unable to examine associations with 252 
household size or household income. Additionally, the geographical variables available were 253 
lacking in granularity, meaning we were not able to explore regional differences in more 254 
depth or examine whether regional variation was associated with other sociodemographic 255 
risk factors. 256 
We observed only a modest increase in CMV seroprevalence associated with age, suggesting 257 
that adolescence is not a key transmission period for CMV as it is for EBV (for which 258 
seroprevalence increases from 60% in 11-14 year olds to 93% in 22-24 year olds20). This may 259 
contribute to the lower incidence of CMV-associated (versus EBV-associated) infectious 260 
mononucleosis.4,5  Previous studies have shown that 15% of white British and 44% of British 261 
Pakistani infants were infected with CMV by the age of 2 years, and that seroprevalence was 262 
59% in an adult cohort aged 40-79 years. In combination with our results, this suggests that 263 
after early childhood, there is no ‘key’ age group in which CMV seroprevalence sharply 264 
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increases, and that infection continues to increase during adulthood, particularly for white 265 
British individuals. A better understanding of the interactions between age at CMV 266 
infection, and the development of CMV-related morbidity and mortality, is necessary to be 267 
able to develop an appropriate vaccination strategy, when a vaccine becomes available. 268 
Conclusions 269 
CMV seroprevalence is strongly associated with ethnicity, and modestly increases with age. 270 
A greater understanding of the transmission dynamics of CMV, and the impact of this on 271 
CMV-associated morbidity and mortality, is necessary to inform effective vaccination 272 
strategies when a vaccine for CMV becomes available. 273 
Declarations 274 
Ethics approval and consent to participate 275 
This study was approved by the University College London Research Ethics Committee 276 
(5683/002). The HSE obtained informed written consent for blood samples to be collected 277 
and stored for future analyses.  278 
List of abbreviations 279 
aOR: adjusted odds ratio 280 
BMI: body mass index 281 
CI: confidence interval 282 
CMV: cytomegalovirus 283 
EBV: Epstein-Barr virus 284 
HSE: health survey for England 285 
OR: odds ratio 286 
RU: relative units 287 
UK: United Kingdom 288 
VCA: virus capsid antigen 289 
Consent for publication 290 
Not applicable 291 
12 
 
Availability of data and materials 292 
The data used in this study was under license from the Health Survey for England, and so are 293 
not publicly available, but can be requested from the HSE. 294 
Competing interests 295 
GT reports personal fees from Genocea Biosciences, outside the submitted work. CJ is an 296 
Associate Editor at BMC Public Health. All other authors have no competing interests. 297 
Funding 298 
This work was supported by the Wellcome Trust [204419]. The funding source has no role in 299 
the study design, collection, analysis or interpretation of the data, the writing of the paper 300 
or the decision to submit for publication. The corresponding author had full access to all 301 
data in the study and had final responsibility to submit the paper for publication. 302 
Authors' contributions 303 
HRS, JL and GT designed the study. OT and GT conducted the serological testing. JRW 304 
conducted the data analysis and drafted the paper. JRW, CJ, HRS, JL and GT interpreted the 305 
results. All authors critically revised the paper and approved the final version for 306 
publication. 307 
Acknowledgements 308 
We thank our colleagues at UCL and NatCen Social Research, and the interviewers, research 309 
nurses and participants of the Health Survey for England, and Shaun Scholes for assistance 310 
weighting the HSE data for analysis. 311 
References 312 
 1. Zuhair, M. et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A 313 
systematic review and meta-analysis. Rev. Med. Virol. 29, e2034 (2019). 314 
2. Arens, R., Remmerswaal, E. B. M., Bosch, J. A. & Lier, R. A. W. van. 5th International 315 
Workshop on CMV and Immunosenescence - A shadow of cytomegalovirus infection on 316 
immunological memory. Eur. J. Immunol. 45, 954–957 (2015). 317 
3. Navarro, D. Expanding role of cytomegalovirus as a human pathogen: Cytomegalovirus 318 
and Human Disease. J. Med. Virol. 88, 1103–1112 (2016). 319 
13 
 
4. Evans, A. Infectious mononucleosis and related syndromes. Am. J. Med. Sci. 276, 325–320 
340 (1978). 321 
5. Landolfo, S., Gariglio, M., Gribaudo, G. & Lembo, D. The human cytomegalovirus. 322 
Pharmacol. Ther. 98, 269–297 (2003). 323 
6. Gkrania-Klotsas, E. et al. Seropositivity and Higher Immunoglobulin G Antibody Levels 324 
Against Cytomegalovirus Are Associated With Mortality in the Population-Based 325 
European Prospective Investigation of Cancer–Norfolk Cohort. Clin. Infect. Dis. 56, 1421–326 
1427 (2013). 327 
7. Simanek, A. M. et al. Seropositivity to cytomegalovirus, inflammation, all-cause and 328 
cardiovascular disease-related mortality in the United States. PloS One 6, e16103 (2011). 329 
8. Wang, G. C. et al. Cytomegalovirus infection and the risk of mortality and frailty in older 330 
women: a prospective observational cohort study. Am. J. Epidemiol. 171, 1144–1152 331 
(2010). 332 
9. Strandberg, T. E., Pitkala, K. H. & Tilvis, R. S. Cytomegalovirus antibody level and 333 
mortality among community-dwelling older adults with stable cardiovascular disease. 334 
JAMA 301, 380–382 (2009). 335 
10. Lepiller, Q., Tripathy, M. K., Di Martino, V., Kantelip, B. & Herbein, G. Increased HCMV 336 
seroprevalence in patients with hepatocellular carcinoma. Virol. J. 8, 485 (2011). 337 
11. Gkrania-Klotsas, E. et al. Higher Immunoglobulin G Antibody Levels Against 338 
Cytomegalovirus Are Associated With Incident Ischemic Heart Disease in the Population-339 
Based EPIC-Norfolk Cohort. J. Infect. Dis. 206, 1897–1903 (2012). 340 
12. Sundqvist, E. et al. Cytomegalovirus seropositivity is negatively associated with multiple 341 
sclerosis. Mult. Scler. Houndmills Basingstoke Engl. 20, 165–173 (2014). 342 
13. van de Berg, P. J. E. J. et al. Cytomegalovirus infection reduces telomere length of the 343 
circulating T cell pool. J. Immunol. Baltim. Md 1950 184, 3417–3423 (2010). 344 
14. Hosie, L. et al. Cytomegalovirus-Specific T Cells Restricted by HLA-Cw*0702 Increase 345 
Markedly with Age and Dominate the CD8+ T-Cell Repertoire in Older People. Front. 346 
Immunol. 8, (2017). 347 
15. Pachnio, A. et al. Cytomegalovirus Infection Leads to Development of High Frequencies 348 
of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 349 
12, e1005832 (2016). 350 
14 
 
16. Sung, H. & Schleiss, M. R. Update on the current status of cytomegalovirus vaccines. 351 
Expert Rev. Vaccines 9, 1303–1314 (2010). 352 
17. Modlin, J. F. et al. Vaccine Development to Prevent Cytomegalovirus Disease: Report 353 
from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39, 233–239 (2004). 354 
18. Dowd, J. B., Aiello, A. E. & Alley, D. E. Socioeconomic Disparities in the Seroprevalence of 355 
Cytomegalovirus Infection in the U.S. Population: NHANES III. Epidemiol. Infect. 137, 58–356 
65 (2009). 357 
19. Levine, H. et al. Seroepidemiology of Epstein-Barr virus and cytomegalovirus among 358 
Israeli male young adults. Ann. Epidemiol. 22, 783–788 (2012). 359 
20. Winter, J. R. et al. Predictors of Epstein-Barr virus serostatus in young people in England. 360 
BMC Infect. Dis. 19, 1007 (2019). 361 
21. Lachmann, R. et al. Cytomegalovirus (CMV) seroprevalence in the adult population of 362 
Germany. PLoS ONE 13, (2018). 363 
22. Pembrey, L. et al. Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella 364 
Zoster Virus among Pregnant Women in Bradford: A Cohort Study. PLoS ONE 8, (2013). 365 
23. Pembrey, L. et al. Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection 366 
in the first two years of life: a cohort study in Bradford, UK. BMC Infect. Dis. 17, 220 367 
(2017). 368 
24. Pembrey, L., Waiblinger, D., Griffiths, P. & Wright, J. Age at cytomegalovirus, Epstein 369 
Barr virus and varicella zoster virus infection and risk of atopy: The Born in Bradford 370 
cohort, UK. Pediatr. Allergy Immunol. 30, 604–613 (2019). 371 
25. Deverill, C. et al. Health Survey for England 2002: The Health of Children and Young 372 
People. Methodology & Documentation. (The Stationary Office, 2002). 373 
26. Goscé, L., Winter, J. R., Taylor, G. S., Lewis, J. E. A. & Stagg, H. R. Modelling the dynamics 374 
of EBV transmission to inform a vaccine target product profile and future vaccination 375 
strategy. Sci. Rep. 9, 1–9 (2019). 376 
27. Office for National Statistics. Estimates of the population for the UK, England and Wales, 377 
Scotland and Northern Ireland. 378 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/pop379 
ulationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorth380 
ernireland (2018). 381 
15 
 
28. Office for National Statistics. Census boundary data [United Kingdom]. 382 
https://census.ukdataservice.ac.uk/get-data/boundary-data.aspx (2011). 383 
29. UK Data Service. Census aggregate data. https://census.ukdataservice.ac.uk/get-384 
data/aggregate-data.aspx (2001). 385 
30. UKB : Data-Field 23054. https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23054. 386 
31. Vyse, A. J., Hesketh, L. M. & Pebody, R. G. The burden of infection with cytomegalovirus 387 
in England and Wales: how many women are infected in pregnancy? Epidemiol. Infect. 388 
137, 526–533 (2009). 389 
 390 
 391 




Table 1: The baseline characteristics of the study population and number and weighted 394 
percentage of individuals seropositive for CMV in England in 2002. 395 
Variable Total number Number CMV 
seropositive (weighted %) 
Total 732 175 (23.7) 
Sex  
 
Male 364 74 (20.4) 
Female 368 101 (26.9) 
Age at last birthday (years)  
 
11-14 208 39 (18.3) 
15-18 212 52 (24.6) 
19-21 156 40 (25.6) 
22-24 156 44 (28.3) 
Ethnicity  
 
White 665 127 (19.2) 
Other 77 48 (61.6) 
BMI  
 
Underweight 60 17 (28.1) 
Healthy weight 418 94 (22.0) 
Overweight 141 34 (23.8) 
Obese 87 25 (29.9) 
Missing 26 5 (19.4) 
EBV serostatus   
EBV-seronegative 547 34 (17.9) 
EBV-seropositive 185 141 (25.7) 
17 
 
Region of England  
 
East of England 78 24 (28.7) 
North East 34 6 (18.0) 
North West 130 27 (19.7) 
Yorkshire and The Humber 82 18 (22.1) 
East Midlands 74 13 (17.0) 
West Midlands 70 16 (23.4) 
London 63 30 (47.9) 
South East 119 20 (16.7) 
South West 82 21 (26.4) 
Smoking status*  
 
Never smoked 86 52 (27.9) 
Current smoker 134 35 (26.0) 
Past smoker 147 36 (24.5) 
Missing 5 3 (60.0) 
Occupational category*  
 
Higher managerial and professional 83 26 (31.6) 
Intermediate occupations 69 20 (28.9) 
Routine and manual occupations 254 61 (24.0) 
Never worked or long-term 
unemployed 
11 2 (18.1) 
Other 55 17 (30.3) 
*Adults aged ≥16 years only (n=472). Percentages account for the weighting of the sample to be 396 
representative of the English population in 2002 with respect to age and sex. BMI: body mass index, CI: 397 
confidence interval, CMV: cytomegalovirus, EBV: Epstein-Barr virus. 398 
  399 
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Table 2: Univariable and multivariable logistic regression models of factors associated with Cytomegalovirus seropositivity in England in 
2002. 
    Whole-population Adults only* 
  Univariable OR (95% CI)  Multivariable aOR (95% CI) 
 Multivariable aOR (95% 
CI) 
Sex       
Male 1.00 1.00 1.00 
Female 1.44 (1.02-2.02) 1.39 (0.95-2.05) 1.50 (0.95-2.35) 
Age at last birthday (years)       
11-14 1.00 1.00   
15-18 1.46 (0.89-2.40) 1.55 (0.88-2.75) 1.00 
19-21 1.54 (0.89-2.66) 2.24 (1.21-4.14) 1.05 (0.58-1.91) 
22-24 1.76 (1.04-2.99) 1.77 (0.95-3.29) 0.74 (0.38-1.46) 
Ethnicity       
White 1.00 1.00 1.00 
Other 6.75 (4.23-10.77) 6.22 (3.47-11.14) 6.98 (3.18-15.32) 
BMI       
19 
 
Underweight 1.39 (0.77-2.52) 1.18 (0.62-2.24) 0.98 (0.50-1.93) 
Healthy weight 1.00 1.00 1.00 
Overweight 1.11 (0.71-1.74) 1.15 (0.71-1.86) 0.84 (0.47-1.53) 
Obese 1.52 (0.90-2.56) 1.50 (0.81-2.77) 1.06 (0.40-2.76) 
EBV serostatus       
Negative 1.00 1.00 1.00 
Positive 1.59 (1.06-2.39) 1.21 (0.76-1.92) 2.08 (1.06-4.09) 
Region of England       
East of England 1.00 1.00 1.00 
North East 0.54 (0.18-1.66) 0.51 (0.17-1.50) 0.57 (0.16-2.02) 
North West 0.61 (0.31-1.19) 0.62 (0.31-1.22) 0.60 (0.25-1.40) 
Yorkshire and The Humber 0.70 (0.33-1.51) 0.67 (0.30-1.51) 0.62 (0.26-1.47) 
East Midlands 0.51 (0.21-1.19) 0.52 (0.21-1.26) 0.70 (0.24-2.04) 
West Midlands 0.76 (0.35-1.63) 0.81 (0.36-1.79) 0.53 (0.18-1.60) 
London 2.28 (1.13-4.61) 1.18 (0.52-2.69) 1.28 (0.45-3.61) 
South East 0.50 (0.24-1.03) 0.43 (0.20-0.93) 0.44 (0.17-1.14) 
20 
 
South West 0.89 (0.46-1.70) 1.09 (0.55-2.15) 0.72 (0.29-1.78) 
Smoking status       
Never smoked 1.00 - 1.00 
Current smoker 0.91 (0.54-1.51) - 1.08 (0.58-2.01) 
Smoked in past 0.84 (0.51-1.38) - 0.96 (0.54-1.69) 
Occupational category       
Higher managerial and 
professional 1.00 - 1.00 
Intermediate occupations 0.88 (0.44-1.76) - 0.66 (0.31-1.42) 
Routine and manual occupations 0.68 (0.40-1.18) - 0.63 (0.32-1.24) 
Never worked or long-term 
unemployed 0.48 (0.09-2.45) - 0.40 (0.07-2.14) 
Other 0.94 (0.46-1.93)   0.47 (0.17-1.28) 
*Adults aged ≥16 years only (n=472). †16-18 years for ‘adult-only’ model. Odds ratios account for the weighting of the sample to be representative of the English 
population in 2002 with respect to age and sex. The ‘whole population’ multivariable model included age, sex, CMV serostatus, ethnicity, BMI and region of England. The 
‘adults only’ multivariable model included all variables shown in the table. aOR: adjusted odds ratio, BMI: body mass index, CI: confidence interval, CMV: cytomegalovirus, 
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